{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:53:44Z","timestamp":1788497624724,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PT20\/00138"],"award-info":[{"award-number":["PT20\/00138"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI20\/00945"],"award-info":[{"award-number":["PI20\/00945"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI23\/01896"],"award-info":[{"award-number":["PI23\/01896"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijid.2025.108306","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T23:22:17Z","timestamp":1765063337000},"page":"108306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Intensification with a CCR5 inhibitor at antiretroviral therapy initiation modulates interleukin-18 and inflammation-driven immune pathways in people with HIV"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0325-3735","authenticated-orcid":false,"given":"Erick","family":"De La Torre Tarazona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Calder\u00f3n-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Fons-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s Luis","family":"Ruiz-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Olalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Alcaraz Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rodr\u00edguez D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Alcam\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Muriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Serrano-Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108306_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijid.2025.108306_bib0002","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/v11030200","article-title":"Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART","volume":"11","author":"Zicari","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ijid.2025.108306_bib0003","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3390\/v16020219","article-title":"Examining chronic inflammation, immune metabolism, and T cell dysfunction in HIV infection","volume":"16","author":"Mu","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ijid.2025.108306_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/7316456","article-title":"HIV-related immune activation and inflammation: current understanding and strategies","volume":"2021","author":"Lv","year":"2021","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ijid.2025.108306_bib0005","article-title":"Long-term changes of inflammatory biomarkers in individuals on suppressive three-drug or two-drug antiretroviral regimens","volume":"13","author":"Serrano-Villar","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2025.108306_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013188","article-title":"Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients","volume":"5","author":"Funderburg","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2025.108306_bib0007","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2012-06-436345","article-title":"The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial","volume":"121","author":"Hunt","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ijid.2025.108306_bib0008","article-title":"Effects of combined CCR5\/integrase inhibitors-based regimen on mucosal immunity in HIV-infected patients na\u00efve to antiretroviral therapy: a pilot randomized trial","volume":"12","author":"Serrano-Villar","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijid.2025.108306_bib0009","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/QAD.0000000000000810","article-title":"Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery","volume":"29","author":"Cillo","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.108306_bib0010","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/QAD.0000000000001515","article-title":"Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers","volume":"31","author":"Kim","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.108306_bib0011","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAD.0000000000000066","article-title":"Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection","volume":"28","author":"Puertas","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.108306_bib0012","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/cid\/ciy781","article-title":"Safety and impact of low-dose methotrexate on endothelial function and inflammation in individuals with treated human immunodeficiency virus: AIDS clinical trials group study A5314","volume":"68","author":"Hsue","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108306_bib0013","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/infdis\/jiz344","article-title":"A randomized, placebo-controlled, pilot clinical trial of dipyridamole to decrease human immunodeficiency virus\u2013associated chronic inflammation","volume":"221","author":"Macatangay","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2025.108306_bib0014","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/QAD.0b013e32831cf595","article-title":"Enhanced levels of the CCR7 ligands CCL19 and CCL21 in HIV infection: correlation with viral load, disease progression and response to highly active antiretroviral therapy","volume":"23","author":"Dam\u00e5s","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.108306_bib0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12929-018-0490-9","article-title":"The effects of highly active antiretroviral therapy on the serum levels of pro-inflammatory and anti-inflammatory cytokines in HIV infected subjects","volume":"25","author":"Osuji","year":"2018","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.ijid.2025.108306_bib0016","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s12967-019-02172-3","article-title":"The combination of CXCL9, CXCL10 and CXCL11 levels during primary HIV infection predicts HIV disease progression","volume":"17","author":"Yin","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.ijid.2025.108306_bib0017","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.12616","article-title":"Interleukin-18: biological properties and role in disease pathogenesis","volume":"281","author":"Kaplanski","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ijid.2025.108306_bib0018","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3389\/fimmu.2018.00763","article-title":"Unique action of interleukin-18 on T cells and other immune cells","volume":"9","author":"Nakanishi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2025.108306_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194185","article-title":"HIV induces production of IL-18 from intestinal epithelial cells that increases intestinal permeability and microbial translocation","volume":"13","author":"Allam","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2025.108306_bib0020","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1365-2249.2003.02179.x","article-title":"Raised serum levels of interleukin-18 is associated with disease progression and may contribute to virological treatment failure in HIV-1-infected patients","volume":"132","author":"Stylianou","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ijid.2025.108306_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1170208","article-title":"Early on-treatment plasma interleukin-18 as a promising indicator for long-term virological response in patients with HIV-1 infection","volume":"10","author":"Lin","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.ijid.2025.108306_bib0022","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/QAD.0000000000003546","article-title":"Mechanisms of systemic low-grade inflammation in HIV patients on long-term suppressive antiretroviral therapy: the inflammasome hypothesis","volume":"37","author":"Guerville","year":"2023","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.108306_bib0023","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/infdis\/jiad042","article-title":"Interleukin 18 (IL-18) and IL-3 in extracellular vesicles: biomarkers for durable elite control of HIV-1","volume":"227","author":"Poveda","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2025.108306_bib0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1475-2840-9-11","article-title":"The role of interleukin-18 in the metabolic syndrome\u00bb","volume":"9","author":"Tr\u00f8seid","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ijid.2025.108306_bib0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cytogfr.2012.05.002","article-title":"HIV persistence: chemokines and their signalling pathways","volume":"23","author":"Evans","year":"2012","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ijid.2025.108306_bib0026","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/proteomes8030024","article-title":"Profiling of inflammatory proteins in plasma of HIV-1-infected children receiving antiretroviral therapy","volume":"8","author":"Lemma","year":"2020","journal-title":"Proteomes"},{"key":"10.1016\/j.ijid.2025.108306_bib0027","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s12967-019-02172-3","article-title":"The combination of CXCL9, CXCL10 and CXCL11 levels during primary HIV infection predicts HIV disease progression","volume":"17","author":"Yin","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.ijid.2025.108306_bib0028","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-09474-1","article-title":"Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size","volume":"15","author":"De La Torre Tarazona","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2025.108306_bib0029","article-title":"Maraviroc treatment for hospitalized participants with non-severe COVID-19 at risk of progression: a randomized, proof-of-concept clinical trial","author":"Gasca-Capote","year":"2025","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijid.2025.108306_bib0030","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/cid\/ciac249","article-title":"Antiretroviral initiation at \u2265800 CD4+ cells\/mm3 associated with lower human immunodeficiency virus reservoir size","volume":"75","author":"Rasmussen","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108306_bib0031","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1128\/CDLI.8.6.1286-1288.2001","article-title":"Correlation of CD4(+) T-Cell counts estimated by an immunocapture technique (Capcellia) with viral loads in human immunodeficiency virus-seropositive individuals","volume":"8","author":"Kannangai","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.ijid.2025.108306_bib0032","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/1874613601711010024","article-title":"Plasma IP-10 concentrations correlate positively with viraemia and inversely with CD4 counts in untreated HIV infection","volume":"11","author":"Mhandire","year":"2017","journal-title":"Open AIDS J"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225005284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225005284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:49:29Z","timestamp":1783018169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225005284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"alternative-id":["S1201971225005284"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108306","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intensification with a CCR5 inhibitor at antiretroviral therapy initiation modulates interleukin-18 and inflammation-driven immune pathways in people with HIV","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108306"}}